U.S. markets open in 9 hours
  • S&P Futures

    4,151.00
    +9.25 (+0.22%)
     
  • Dow Futures

    32,859.00
    +67.00 (+0.20%)
     
  • Nasdaq Futures

    13,214.25
    +31.00 (+0.24%)
     
  • Russell 2000 Futures

    1,946.20
    +5.10 (+0.26%)
     
  • Crude Oil

    90.58
    -0.18 (-0.20%)
     
  • Gold

    1,802.00
    -3.20 (-0.18%)
     
  • Silver

    20.68
    +0.07 (+0.34%)
     
  • EUR/USD

    1.0196
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.7650
    -2.8400 (-100.00%)
     
  • Vix

    21.29
    +0.14 (+0.66%)
     
  • GBP/USD

    1.2081
    -0.0000 (-0.00%)
     
  • USD/JPY

    134.8670
    -0.1060 (-0.08%)
     
  • BTC-USD

    23,829.23
    +522.11 (+2.24%)
     
  • CMC Crypto 200

    556.76
    +13.88 (+2.56%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    27,986.20
    -263.04 (-0.93%)
     

ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex

·4 min read
ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The Los Angeles-based company is far different from Athenex, developing different kinds of cancer drugs and building its own business model around those plans, but it also has some notable similarities.